CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.

It is not the first time that spiders have served as biological models in the research field of soft robotics. The hydraulic actuation mechanisms they apply to move their limbs when weaving their web or hunting for prey give them powers many roboticists and engineers have drawn inspiration from.

Microorganisms are the oldest, most abundant, and most diverse life forms on earth and offer enormous potential for biotechnological applications. To date, however, only a fraction of them could be isolated and cultivated. The “MicroMATRIX” research project, funded with € 1.5 million by the German Federal Ministry of Education and Research and led by Karlsruhe Institute of Technology (KIT), aims to shed more light on the microbial darkness.

Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

Article - 10/06/2021

New study: vaccine therapy for treating patients with chronic leukaemia

Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

The final report including comprehensive fact sheets of 25 applications is now available online in German and English.

Final chord of the EU-project Smart SMEs - 31/05/2021

Building a sustainable network for natural fibre-based SMEs in the Alpine Space

The European project Smart SMEs came successfully to its end in May 2021 with the final conference, which attracted participants from different parts of Europe.

Final chord of the EU-project Smart SMEs - 31/05/2021

Building a sustainable network for natural fibre-based SMEs in the Alpine Space

The European project Smart SMEs came successfully to its end in May 2021 with the final conference, which attracted participants from different parts of Europe.

Zero Bullshit Company - 31/05/2021

From being thrown away to becoming a recycled product - Stuttgart start-up produces healthy snacks

Throwing away food? The Stuttgart-based start-up Zero Bullshit Company is declaring war on food wastage by making nutrient-rich products largely from food industry leftovers. The three food technologists who created this transparent brand are looking to develop more than just delicious and nutritious products.

Article - 31/05/2021

Tracking down tumour-associated pain in pancreatic cancer

Pancreatic cancer comes along quietly: unnoticed for a long time, it often triggers excruciating pain as the tumour progresses. This pain is associated with cancer cells invading pancreatic nerves. Dr. Michael Hirth from Mannheim University Hospital has shed some light on the complex communication between cancer cells and nerve cells. His findings could eventually be used for personalised pain therapies.

Installing the next digital generation of computed tomography at various Baden-Württemberg medical centres (PC3)

The pulp of coffee beans is considered a waste product on coffee plantations, which is usually thrown away or dumped into rivers - with significant negative consequences for climate change and the environment. Macarena San Martín-Ruiz from the University of Stuttgart is working with Coopetarrazú, the largest coffee cooperative in Costa Rica, to find out how the mixture of pulp and husks can be turned into organic compost and thus protect the…

The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.

Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

A particular type of dendritic cell is responsible for the tissue damage that occurs in non-alcoholic steatohepatits (NASH) in mice and humans. The dendritic cells cause aggressive, proinflammatory behavior in T cells, as now discovered by researchers from the German Cancer Research Center (DKFZ) in collaboration with colleagues from Israeli research institutes. Blocking these dendritic cells alleviates symptoms in mice.

Data generated by the healthcare system has enormous potential for improving the quality of patient-centered care. As part of the Health Data Scenarios project, Basel Area Business & Innovation worked with numerous experts from industry and academia in 2020 to develop ten scenarios of what future health data ecosystems could look like. These scenarios are now being discussed and validated together with experts and opinion leaders from…

The Bio-based Industries Joint Undertaking (BBI JU) has signed the grant agreements with 18 new projects, selected for funding under the 2020 Call for proposals. 199 beneficiaries from 26 countries across the EU and beyond will receive BBI JU’s financial support worth €104.5 million. This is the seventh and last BBI JU call which will bring the total investment of the initiative to €821.6 million and the BBI JU’s portfolio to 142 projects.

Signal mechanisms in inflammatory processes - 18/05/2021

Newly discovered substances activate the inflammasome in macrophages

Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

The amount of plastic waste increases every year. Some of this waste is due to plastic packaging used to protect food. As part of the “BioActiveMaterials” project, researchers at the Fraunhofer-Gesellschaft have developed an eco-friendly coating for paper packaging. With this, not only is plastic saved, but the coating of plant-based proteins and waxes also extends the shelf life of the food.